$168.71
-5.37-3.08%
Last update: Nov 10, 4:37 AM
Palvella Therapeutics Inc
PVLANASDAQ
Palvella Therapeutics rose 110.1% from $80.29 to $168.71, ahead of the S&P 500's +10.0%. Its worst day was Jul 20 (−21.0%), and its low came Feb 5 at $76.43.
Story events cover the past 12 months · Times ET
Nov 10, 2025 – Nov 10, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-1.03 missed the $-0.85 estimate on $0.00 revenue.
−3.0% · S&P 500 +0.2%
Palvella Therapeutics shares rose 16.8%, while the S&P 500 rose 0.4%.
+16.8% · S&P 500 +0.4%
Palvella Therapeutics closed at its lowest level of the year, 4.8% below where the year started.
−6.8% · S&P 500 −1.2%
Primary endpoint met with statistically significant improvement (mean change of +2.13; p<0.001) on the Microcystic Lymphatic Malformation Investigator Global Assessment (mLM-IGA)Achieved statistical significance on
+37.1%, the year's best day · S&P 500 +0.7%
EPS of $-1.08 missed the $-0.93 estimate on $0.00 revenue.
+12.6% · S&P 500 +2.9%
EPS of $-1.20 missed the $-0.92 estimate on $0.00 revenue.
−13.0% · S&P 500 −0.3%
Palvella Therapeutics shares fell 21.0%, while the S&P 500 fell 0.2%.
−21.0%, the year's worst day · S&P 500 −0.2%
EPS of $-1.52 missed the $-1.16 estimate on $0.00 revenue.
+8.0% · S&P 500 +1.8%
EPS of $-1.70 beat the $-1.72 estimate on $0.00 revenue (est. $40,000.00).
−3.3% · S&P 500 −4.4%
Where it ended: a close of $168.71 on Nov 10, 2026.
Nothing in the past 12 months.
All PVLA dividend history
